The company remains pre-revenue with R&D expenditures peaking at $8.5 million in 2023Q4, reflecting the high costs associated with advancing its clinical pipeline.
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 724.74K | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 | -724.74K | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | 100% | - | - | - |
| Operating Expenses | 16.93M | 20.2M | 30.8M | 39.5M | 24.31M | 10.1M | 2.43M | 376.86K | 1.12M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 7.9M | 8.49M | 7.89M | 8.08M | 5.36M | 5.25M | 2.14M | 181.12K | 175.58K |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - |
| Research & Development | 9.03M | 11.71M | 22.91M | 31.42M | 18.95M | 4.85M | 295.15K | 195.74K | 946.3K |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -16.93M | -20.2M | -30.8M | -39.5M | -24.31M | -10.1M | -2.43M | -376.86K | -1.12M |
| Operating Margin % | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | - | 34.41% | 22.04% | -62.52% | -140.55% | -315.03% | -546.04% | 66.41% | - |
| EBITDA | -16.61M | -19.83M | 0 | 0 | -24.11M | -10.1M | -2.33M | -376.01K | -1.12M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | 22.13% | - | - | 100% | -138.64% | -333.85% | -519.36% | 66.45% | - |
| D&A (Non-Cash Add-back) | 0 | 0 | 30.8M | 39.5M | 194.71K | 591 | 105.77K | 846 | 1.02K |
| EBIT | -16.61M | -19.83M | -29.88M | -39.24M | -24.31M | -10.1M | -2.43M | -376.86K | -1.12M |
| Net Interest Income | 300.56K | 297.97K | 342.87K | 364.69K | 0 | -2.41K | -1.35M | -469.17K | -557.67K |
| Interest Income | 314.61K | 311.37K | 361.37K | 398.41K | 182.8K | 0 | 105.18K | 201 | 0 |
| Interest Expense | 14.05K | 13.4K | 18.5K | 33.73K | 182.8K | 2.41K | 1.45M | 469.37K | 557.67K |
| Other Income/Expense | 322.79K | 354.02K | 899.6K | 259.75K | -11.91K | 1.59M | -1.35M | -469.17K | -557.67K |
| Pretax Income | -16.61M | -19.85M | -29.9M | -39.24M | -24.32M | -8.52M | -3.78M | -846.03K | -1.68M |
| Pretax Margin % | - | - | - | - | - | - | - | - | - |
| Income Tax | 17.02K | 18.89K | 19.51K | 16.95K | 20.78K | 6K | 800 | 800 | 800 |
| Effective Tax Rate % | -0.1% | -0.1% | -0.07% | -0.04% | -0.09% | -0.07% | -0.02% | -0.09% | -0.05% |
| Net Income | -16.63M | -19.86M | -29.92M | -39.26M | -24.34M | -8.52M | -3.78M | -846.83K | -1.68M |
| Net Margin % | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | 42.5% | 33.6% | 23.79% | -61.31% | -185.61% | -125.24% | -346.77% | 49.6% | - |
| Net Income (Continuing) | -16.63M | -19.86M | -29.92M | -39.26M | -24.34M | -8.52M | -3.78M | -846.83K | -1.68M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -2.37 | -5.48 | -18.00 | -33.00 | -29.00 | -11.60 | -24.80 | -6.20 | 5.63 |
| EPS Growth % | 42.66% | 69.56% | 45.45% | -13.79% | -150% | 53.23% | -300% | -210.12% | - |
| EPS (Basic) | - | -5.48 | -18.00 | -33.00 | -29.00 | -11.60 | -24.80 | -6.20 | 5.63 |
| Diluted Shares Outstanding | 7.02M | 3.63M | 1.66M | 1.19M | 975.82K | 739.54K | 153.08K | 138.53K | 101.98K |
| Basic Shares Outstanding | 7.02M | 3.63M | 1.66M | 1.19M | 975.82K | 739.54K | 153.08K | 138.53K | 101.98K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
Clinical trial funding shortfall
As indicated by the company's historical financial filings, Reviva's cost structure is dominated by R&D expenditures, which reached a peak of $8.5 million in 2023Q4, reflecting the heavy capital requirements necessary to advance the brilaroxazine clinical program through critical late-stage regulatory milestones.
The concentration of spending on clinical trial management and CRO fees underscores the company's singular focus on its lead asset. Investors should monitor whether the recent moderation in R&D spending to $1.4 million in 2026Q1 represents a sustainable efficiency gain or a forced reduction due to limited capital availability.
Based on reported quarterly figures, Reviva consistently utilizes stock-based compensation, with a notable $919.1K expense recorded in 2025Q1, which serves to preserve cash while simultaneously increasing the potential for future equity dilution for existing shareholders as the company navigates its pre-revenue development phase.
The reliance on equity-based incentives is a common feature for clinical-stage firms, yet it complicates the assessment of true operational costs. Analysts should carefully evaluate the impact of these non-cash charges on the net loss trajectory, as they mask the underlying cash burn required to sustain the corporate structure.
According to recent clinical updates, the successful completion of the Phase III RECOVER-1 trial marks a pivotal operational inflection point, shifting the company's income statement focus from early-stage development to the high-stakes regulatory and commercial preparation phase required for a potential New Drug Application.
This milestone validates the efficacy of the lead candidate but also necessitates a shift in capital allocation toward regulatory compliance and commercial readiness. The transition suggests that future income statements will likely reflect higher SG&A costs as the company builds the infrastructure required to support a potential market launch.
As reported in financial statements, the company's cash position of approximately $14.4 million appears insufficient to support ongoing Phase III trial requirements, suggesting that the firm faces a high probability of dilutive financing or a strategic partnership necessity to avoid a significant operational disruption.
The discrepancy between the current cash runway and the capital-intensive nature of late-stage biotech development warrants extreme caution. Investors should consider that the lack of commercial revenue leaves the company entirely exposed to capital market volatility, which may force management to accept unfavorable terms for future funding.
Quick answers to the most common questions about buying RVPH stock.
For fiscal year 2025, Reviva Pharmaceuticals Holdings, Inc. (RVPH) reported total revenue of $0.0M.
Reviva Pharmaceuticals Holdings, Inc. (RVPH) reported a net loss of $19.9M for the fiscal year ending 2025.